- CEO
- Jian Ping Yao
- Full Time Employees
- 2,505
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- AnkeBio Building Hefei AN China 230088
- IPO Date
- Sep 24, 2009
- Business
- Anhui Anke Biotechnology (Group) Co., Ltd. Anhui Anke Biotechnology (Group) Co., Ltd. (300009.SZ) engages primarily in the research, development, production, and sales of biopharmaceuticals, diagnostic reagents, genetic testing products, polypeptide active pharmaceutical ingredients, modern traditional Chinese medicines, chemical synthetic drugs, functional skincare products, and nutritional supplements in China and internationally. The company offers recombinant human growth hormone for injection under the Ansomone brand for growth disorders; recombinant human interferon alpha 2b in forms including lyophilized powder, liquid injection, prefilled syringe, cream, eye drops, and suppository under the Anterferon brand for chronic hepatitis B, tumors, and leukemia; monoclonal antibody drugs such as trastuzumab injection (Anseiting or ANTRASTUIN) for breast and gastric cancers, bevacizumab for non-small cell lung cancer, and anti-PD1 therapies for advanced cancers; diagnostic kits for anti-sperm antibody (MAR), semen analysis including DNA fragmentation, acrosin, morphology, viability, and leukocyte detection, as well as hormone tests like AMH and leptin; peptide drugs including etiprate, thymopentin, thymalfasin, oxytocin, somatostatin, carbetocin, salmon calcitonin, octreotide acetate, and atosiban acetate; modern Chinese medicines such as blood-activating pain-relieving plasters, musk bone-strengthening cream, snake bile川贝 liquid, jujube seed mixture, wind oil, dog skin cream, and frostbite ointment; chemical synthetics like amoxicillin granules and capsules, cefixime granules, tenofovir fumarate tablets, and azithromycin powder; functional skincare items including hyaluronic acid essences, peptide anti-wrinkle creams, repair dressings, and soothing masks; and functional nutritionals under brands like Anke Youer featuring GABA-prebiotic composites for children's growth, sleep, and weight management. Founded in 2000 and headquartered in Hefei, Anhui province, China, within the High-Tech Development Area, the company operates subsidiaries including Anhui Anke Yuliangqing Pharmaceutical Co., Ltd. for traditional medicines and Anhui Anke Hengyi Pharmaceutical Co., Ltd. for synthetics, with sales networks spanning over 30 Chinese provinces and expanding international partnerships; it maintains GMP and ISO9001-certified facilities and participates in national projects like 863 Programs. Recent developments include receipt of NMPA clinical trial approval in July 2025 for the Class 1 innovative anti-HER2 drug AK2024 injection (BSI-128) developed with Biosion; a global strategic cooperation framework agreement with Weisheng Pharmaceutical-B in 2025 to accelerate commercialization of long-acting growth hormone in China; leading an investment in November 2025 to increase capital in Bosun J Medicine (Boshenji) and secure nationwide exclusive commercialization rights to its leading CD7-CAR-T cell therapy; launch of dual-specification Anseiting trastuzumab highlighted at the 20th Shanghai International Breast Cancer Forum in November 2025; and introduction of long-acting growth hormone Shengnuowa at reproductive medicine events in November 2025, alongside recognition as a 2024 Anhui manufacturing亩均效益 leader.